ZURICH (Reuters) – Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefit.

https://www.reuters.com/article/us-novartis-heart-drug/novartis-launches-heart-drug-counter-offensive-idUSKBN1DD23N